Biotechs--and indeed any high price-to-earnings stocks perceived as risky--have taken more than their share of punishment in the nervous sell off of the last few weeks. Nektar Therapeutics (NKTR), for example, closed yesterday August 21 at $17.79. That's down from $23.23 a share on July 23. That downward volatility hasn't been kind to the call […]
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.
